Lineage Cell Therapeutics (LCTX)
(Delayed Data from AMEX)
$0.93 USD
+0.02 (2.20%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $0.93 0.00 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Lineage Cell Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 35 | 58 | 58 | 42 | 31 |
Receivables | 1 | 0 | 51 | 0 | 24 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 2 | 2 | 2 | 3 |
Total Current Assets | 38 | 60 | 112 | 44 | 58 |
Net Property & Equipment | 5 | 6 | 5 | 6 | 8 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 57 | 57 | 57 | 58 | 59 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 101 | 124 | 175 | 108 | 125 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 9 | 28 | 7 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 1 | 1 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 11 | 9 | 18 | 0 | 0 |
Total Current Liabilities | 18 | 19 | 47 | 8 | 6 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 19 | 30 | 35 | 2 | 4 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 39 | 52 | 84 | 13 | 14 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 451 | 440 | 435 | 394 | 387 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -385 | -363 | -337 | -294 | -273 |
Other Equity | -4 | -5 | -7 | -5 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 62 | 72 | 91 | 95 | 111 |
Total Liabilities & Shareholder's Equity | 101 | 124 | 175 | 108 | 125 |
Total Common Equity | 62 | 72 | 91 | 95 | 111 |
Shares Outstanding | 174.90 | 169.90 | 168.50 | 149.90 | 149.70 |
Book Value Per Share | 0.35 | 0.42 | 0.54 | 0.63 | 0.74 |
Fiscal Year End for Lineage Cell Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 38 | 44 | 35 | 41 | 46 |
Receivables | 0 | 0 | 1 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 2 | 2 | 2 | 2 |
Total Current Assets | 40 | 46 | 38 | 43 | 48 |
Net Property & Equipment | 2 | 2 | 5 | 5 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 57 | 57 | 57 | 57 | 57 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 103 | 108 | 101 | 106 | 112 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 6 | 6 | 5 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 9 | 10 | 11 | 10 | 10 |
Total Current Liabilities | 15 | 17 | 18 | 16 | 16 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 19 | 18 | 19 | 21 | 22 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 36 | 37 | 39 | 39 | 40 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 468 | 467 | 451 | 450 | 448 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -397 | -391 | -385 | -380 | -373 |
Other Equity | -4 | -4 | -4 | -4 | -4 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 67 | 71 | 62 | 67 | 71 |
Total Liabilities & Shareholder's Equity | 103 | 108 | 101 | 106 | 112 |
Total Common Equity | 67 | 71 | 62 | 67 | 71 |
Shares Outstanding | 188.80 | 188.80 | 174.90 | 174.90 | 174.70 |
Book Value Per Share | 0.35 | 0.38 | 0.35 | 0.38 | 0.41 |